Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by enriquesuaveon Apr 27, 2023 8:42pm
163 Views
Post# 35418320

RE:RE:RE:RE:RE:RE:RE:New Data Format

RE:RE:RE:RE:RE:RE:RE:New Data Format
CancerSlayer wrote:

enriquesuave wrote: I would say more around 45-55% durable CR as some of the IR patients convert to CR. 

 

My overall 30+% durable CR figure includes the first 12.  Excluding them, I think it's possible we get to 30-40+% durable CR if all goes well.  Except for the two IRs/unknowns at 450 days, all IRs appear to end up NR.  Hopefully, that IR trend changes over time as more patients are treated & PIs gain additional experience under the optimized protocol.


So we are on the same page.  In the swimmers plot and the chart, the initial 12 are included at 90 days.  If we remove them at 90 days data, then we could see 63%  CR ( instead of 54%) or 25out of 40 and 12% IR or total response of 75%.  Anytime CR would be 29 out of 40 or 73% plus 12% IR. Total response of 85%.  We beat combination of N-803 plus BCG so far. We are being manipulated for sure. Perhaps next week we get a big move up. Last year we went down early May, and when market caught up with data we popped end of May if I recall.  

<< Previous
Bullboard Posts
Next >>